Search - tctmd.com

Displaying 81 - 100 of 1378

Sort: Relevancy | Date

Presentation TCT 2022

Two-Year Outcomes of the Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

Presenter: Pablo Salinas

September 19, 2022

Presentation TCT 2022

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

Presenter: Jonas Haener

September 19, 2022

Presentation TCT 2022

TCT 51: Assessment of Durable Polymer and Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction

Presenter: Gustavo Araújo

September 17, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Conference News EuroPCR 2022

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

Yael L. Maxwell

May 17, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for March 2022

Caitlin E. Cox

April 01, 2022

News Daily News

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

Michael O'Riordan

March 30, 2022

News Features

Bloodlines: How Far Should Cardiologists Go in Treating Family?

Todd Neale

March 10, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

News Features

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

Michael O'Riordan

December 23, 2021

Presentation TCT 2021

BIO-RESORT: Five-Year Outcomes from a Randomized Trial of Three Drug-Eluting Stents in Patients With Coronary Artery Disease

Presenter: Eline Ploumen

November 06, 2021

News Conference News TCT 2021

DCBs in Coronaries? Some Good News, but More Work Needed

L.A. McKeown

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

News Conference News TCT 2021

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

Yael L. Maxwell

November 05, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Daily News

IVUS-Guided PCI Tied to Better Long-term Outcomes After Acute MI

Todd Neale

October 29, 2021

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Conference News VIVA 2021

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

L.A. McKeown

October 12, 2021

News Conference News VIVA 2021

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

L.A. McKeown

October 08, 2021

Advertisement

Two-Year Outcomes of the Randomized Second-Generation Drug-Eluting Stents in Diabetes (SUGAR) Trial

TCT 167: Percutaneous Coronary Intervention with Ultrathin-Strut Biodegradable versus Thin-Strut Durable Polymer Drug-Eluting Stents of Lesions Requiring Multiple Stents: A Lesion-Level Subgroup Analysis of the Combined BIOSCIENCE and BIOSTEMI Randomized…

TCT 51: Assessment of Durable Polymer and Biodegradable Polymer Drug-Eluting Stents After Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction

High Lp(a) May Predict Risk of CV and Limb Events in PAD

Shorter DAPT Sufficient Even in Complex HBR Patients: MASTER DAPT

TCTMD’s Top 10 Most Popular Stories for March 2022

Clopidogrel Superior to ‘Divine’ Aspirin Monotherapy in Secondary Prevention

Bloodlines: How Far Should Cardiologists Go in Treating Family?

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

FFR’s Future: Negative Trials Spur Debate Over Technology’s Role

BIO-RESORT: Five-Year Outcomes from a Randomized Trial of Three Drug-Eluting Stents in Patients With Coronary Artery Disease

DCBs in Coronaries? Some Good News, but More Work Needed

More DAPT Duration Data, More Calls to Tailor to Individual Patients

TAVI Edges Out Surgery in 2-Year Costs for Low-risk Patients: PARTNER 3

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

IVUS-Guided PCI Tied to Better Long-term Outcomes After Acute MI

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Good Long-term Results With FANTOM BVS, but More Data Needed

EMINENT: Better Patency With DES Over BMS for Fem-Pop Lesions

Diverting or Swirling, New Blood-Flow Tech Shows Promise for CLTI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content